EDECRIN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jan 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
EDECRIN by Bausch + Lomb is clinical pharmacology pharmacokinetics and metabolism edecrin acts on the ascending limb of the loop of henle and on the proximal and distal tubules. Approved for edema. First approved in 1967.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EDECRIN (ethacrynic acid) is a loop diuretic that acts on the ascending limb of the loop of Henle and proximal/distal tubules to increase urinary sodium, chloride, and water excretion. It is indicated for edema management and is effective in patients with significant renal insufficiency. The drug has rapid onset (30 minutes oral, 5 minutes IV) with peak diuresis at approximately 2 hours.
$0.517MPart D
LOE ApproachingMinimal commercial activity with only $517K annual Part D spending and 229 claims in 2023, signaling a mature, niche product with likely small brand team and declining career growth opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism EDECRIN acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several…
Indications (1)
Worked on EDECRIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.